Skip to main content
Top
Published in: Pediatric Rheumatology 1/2020

01-12-2020 | Juvenile Rheumatoid Arthritis | Case Report

Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype

Authors: S. L. N. Clarke, L. Robertson, G. I. Rice, L. Seabra, T. N. Hilliard, Y. J. Crow, A. V. Ramanan

Published in: Pediatric Rheumatology | Issue 1/2020

Login to get access

Abstract

Background

STING-associated vasculopathy with onset in infancy (SAVI) is a type 1 interferonopathy manifesting as a pulmonary and vascular syndrome resulting from gain-of-function mutations in TMEM173, the gene encoding STING. Familial reports in the literature are sparse.

Case presentation

We report a case series of SAVI in a three generation kindred, with a phenotype of interstitial lung disease (ILD) and rheumatoid factor positive polyarticular juvenile idiopathic arthritis (JIA). Current and historical medical records were reviewed for clinical and laboratory information. Whole blood from cases 1 and 2, plus stored appendicectomy tissue from case 3, underwent DNA sequencing of the TMEM173 gene. Peripheral blood RNA was obtained from cases 1 and 2 for functional assessment of the TMEM173 mutation. DNA sequencing identified the same heterozygous TMEM173 mutation (c.463G > A; p.Val155Met) in all three cases, consistent with a diagnosis of the autosomal dominant condition SAVI. Functional assessment of this mutation identified a prominent interferon signature which was confirmed on repeat testing.

Conclusions

SAVI presented in this family as ILD with early onset juvenile rheumatoid arthritis. This condition should be considered in all rheumatoid arthritis patients with early-onset ILD and in all JIA patients with ILD.
Literature
1.
go back to reference Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507–18.CrossRef Liu Y, et al. Activated STING in a vascular and pulmonary syndrome. N Engl J Med. 2014;371:507–18.CrossRef
2.
go back to reference Jeremiah N, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124:5516–20.CrossRef Jeremiah N, et al. Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations. J Clin Invest. 2014;124:5516–20.CrossRef
3.
go back to reference Picard C, et al. Severe pulmonary fibrosis as the first manifestation of Interferonopathy (TMEM173 mutation). Chest. 2016;150:e65–71.CrossRef Picard C, et al. Severe pulmonary fibrosis as the first manifestation of Interferonopathy (TMEM173 mutation). Chest. 2016;150:e65–71.CrossRef
4.
go back to reference König N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76:468–72.CrossRef König N, et al. Familial chilblain lupus due to a gain-of-function mutation in STING. Ann Rheum Dis. 2017;76:468–72.CrossRef
5.
go back to reference Rice GI, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12:1159–69.CrossRef Rice GI, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12:1159–69.CrossRef
6.
go back to reference Sanchez GAM, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–52.CrossRef Sanchez GAM, et al. JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. J Clin Invest. 2018;128:3041–52.CrossRef
7.
go back to reference Frémond ML, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138:1752–5..CrossRef Frémond ML, et al. Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children. J Allergy Clin Immunol. 2016;138:1752–5..CrossRef
8.
go back to reference Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–8.CrossRef Crow YJ. Type I interferonopathies: a novel set of inborn errors of immunity. Ann N Y Acad Sci. 2011;1238:91–8.CrossRef
9.
go back to reference Rodero MP, Crow YJ. Type I interferon–mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213:2527–38.CrossRef Rodero MP, Crow YJ. Type I interferon–mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213:2527–38.CrossRef
10.
go back to reference Clarke SL, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016;194:639–42.CrossRef Clarke SL, et al. Interstitial lung disease caused by STING-associated vasculopathy with onset in infancy. Am J Respir Crit Care Med. 2016;194:639–42.CrossRef
11.
go back to reference Omoyinmi E, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67:808.CrossRef Omoyinmi E, et al. Stimulator of interferon genes-associated vasculitis of infancy. Arthritis Rheum. 2015;67:808.CrossRef
12.
go back to reference Raffaele CGL, et al. A patient with stimulator of interferon genes–associated vasculopathy with onset in infancy without skin vasculopathy. Rheumatology. 2019;59:905–7. Raffaele CGL, et al. A patient with stimulator of interferon genes–associated vasculopathy with onset in infancy without skin vasculopathy. Rheumatology. 2019;59:905–7.
13.
go back to reference de Carvalho LM, et al. Musculoskeletal disease in MDA5-related type I Interferonopathy: a Mendelian mimic of Jaccoud's Arthropathy. Arthritis Rheum. 2017;69:2081–91.CrossRef de Carvalho LM, et al. Musculoskeletal disease in MDA5-related type I Interferonopathy: a Mendelian mimic of Jaccoud's Arthropathy. Arthritis Rheum. 2017;69:2081–91.CrossRef
14.
go back to reference Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8:2176.CrossRef Rodero MP, et al. Type I interferon-mediated autoinflammation due to DNase II deficiency. Nat Commun. 2017;8:2176.CrossRef
15.
go back to reference Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulmonary Med. 2011;2011:931342.CrossRef Picchianti Diamanti A, Germano V, Bizzi E, Laganà B, Migliore A. Interstitial lung disease in rheumatoid arthritis in the era of biologics. Pulmonary Med. 2011;2011:931342.CrossRef
Metadata
Title
Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype
Authors
S. L. N. Clarke
L. Robertson
G. I. Rice
L. Seabra
T. N. Hilliard
Y. J. Crow
A. V. Ramanan
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Pediatric Rheumatology / Issue 1/2020
Electronic ISSN: 1546-0096
DOI
https://doi.org/10.1186/s12969-020-00425-w

Other articles of this Issue 1/2020

Pediatric Rheumatology 1/2020 Go to the issue